"Pharma and Imaging Companies interactions have progressed" -

2nd Quarter 2010

Erik Christensen, MD PhD

Chief Executive Officer

Ruben Ekbråten

Financial Controller

Henrik Lund, MD PhD

Chairman BoD

DiaGenic

FOR EARLIER DISEASE DETECTION

Agenda: 2nd Quarter 2010 Presentation

- 2nd Quarter Highlights

- Product Development & Commercial Strategies

- 2nd Quarter Finance

- Outlook

2ⁿᵈ Quarter 2010 Highlights

- Distributor sales continue to be slow and below expectations
  - BCtect® is promoted by the first clinic in UK and 6 more is starting after summer
- Strength of IP and competitive position drives Pharma and PET imaging companies' interest in DiaGenic. Multiple interactions ongoing in Alzheimers area (ADtect®/MCItect®)
- New Board of Directors elected – more focus on partnering options for DiaGenic

Post quarter end

- Notice of Allowance on a family 3 Patent covering 30 countries in Europe

Agenda: 2nd Quarter 2010 Presentation

- 🔴 2nd Quarter Highlights

- 🔴 Product Development & Commercial Strategies

- 🔴 2nd Quarter Finance

- 🔴 Outlook

DiaGenic

Product portfolio
Molecular Diagnostics

Pre-clinical research	Clinical studies	Prototype development	Regulatory (CE)	Sales & Marketing	Reimbursement General Sales

ADtect — DiaGenic for early Alzheimer's Disease detection

MCItect — DiaGenic for early Alzheimer's Disease detection

BCtect — DiaGenic for early Breast Cancer detection

PDtect — DiaGenic for early Parkinsons Disease detection

Solid IP, backed by 10 years of R&D
> 100 patents accepted or granted

Patent overview
17th of August 2010

Countries/Region	Family 1 (WO 98/49342) 2017			Family 2 (WO 2004/046382) 2023			Family 3 (WO 2005/118851) 2024		
Expiry year	G	A	P	G	A	P	G	A	P
US	1	0	2	0	0	1	0	0	1
Europe*	2	0	1	0	0	0	0	0	1
Europe**	0	0	0	1	0	0	0	1	0
Norway	2	0	0	0	0	1	0	0	1
Japan	1	0	0	0	0	1	0	0	1
Canada	0	0	0	0	0	1	0	0	1
Hong Kong	2	0	0	0	0	1	0	0	1
China	0	0	0	0	0	1	0	0	1
Australia	0	0	0	1	0	0	0	0	1
New Zealand	0	0	0	1	0	0	1	0	0
India	0	0	0	1	0	0	0	0	1
South Africa	0	0	0	1	0	0	1	0	0
ARIPO*	0	0	0	0	0	1	0	0	1

- G — Number of patents granted
- A — Number of patents accepted by examiner
- P — Number of patents in progress

Europe*
Designated countries
Austria, Belgium, Switzerland, Cyprus, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, The Netherlands, Portugal and Sweden

Europe**
Designated countries
Austria, Belgium, Switzerland, Cyprus, Germany, Denmark, Spain, Finland, France, United Kingdom Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, Netherlands, Portugal, Romania, Sweden, Slovenia, Slovakia and Turkey

ARIPO* (African Regional Intellectual Property Organization)
Designated countries
Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe

List of granted patents/allowed patent applications
US 6720138; EP 0979308; EP 1323728; NO 317247; NO 20040371; JP 4163758; HK 1026003; HK 03109502.9; AU 2003286262; NZ 540750; IN 2701/DELNP/2005; ZA 2005/03797; ZA 2006/10644; HK 1057217; NO 327084; EP 156557431

Impact of Clinical Accuracy

- Two independent validation studies of ADtect® showed a 71.6% and 71.5% agreement of the ADtect® test with the clinical diagnosis

- Clinical diagnosis is not always in agreement with true pathology

- Among the 16 AD cases and two (2) controls where CSF biomarkers also was included 13 of the AD subjects and both controls were correctly predicted

- Assuming an accuracy of 80% for the clinical diagnosis compared with definite neurologically confirmed AD, the agreement of the 96-gene array test is most likely in the range 85%-90%

How closely is the gene expression in blood of Alzheimer's disease patients associated with the known biology of the disease?

- ◆ It was found that 32 of 84 genes in ADtect® encode proteins with a biological function associated with AD, brain or neuronal function.

  - ◆ Four of them are also listed in the current AlzGene database.

- ◆ The identity of 12 genes included in the test could not be found in available databases.

ICAD 2010
Hot Topic Poster Session

FOR EARLY DISEASE SIGNATURES

DiaGenic

Business/Partnering model

| Research | Clinical development | Production | Sales & Marketing |

Two-segment business model

MDx-business

Molecular Diagnostics

Rx– business

Biomarker for Prescription drug use

MDx-business
Molecular Diagnostics

BCtect

early detection of
Breast Cancer

BCtect® distribution in Europe

- 5 distributors covering 10 countries
- Key activities
  - Private clinics in UK ready to promote BCtect:
    - The London Breast Clinic.
    - The London Clinic,
    - The Harley Street Breast Clinic,
    - Nuffield Health, Bristol and Glascow,
    - Aspen Healthcare, Parkside Hospital Wimbledon,
    - BMI Healthcare, Syon.
  - Private clinic in Finland signed contract
- Congresses:
  - European Cancer Research Association, Oslo
  - IMPACT 2009 Breast Cancer Conference, Brussels

ADtect® distribution in Europe

- 6 distributors covering 20 countries
  - Main support focus area:
    - Ferrer Step wise roll out:
      - Q2-10: Spain and Germany
      - Q4-10: Benelux, France and Portugal
  - The distributors follows the scientific sales model
    - Scientific and commercial advisor board initiated
- Congresses:
  - International Congress on Alzheimer's Disease
    - 2 presentations, one in hot topic section

Two-segment business model

Rx– **business**

Biomarker for Prescription drug use

Pharma Strategy

Development

Partnering

Commercialization

DiaGenic

DiaGenic's Partner Approach
August 2010

Development status

Potential pharma partner:
96 gene signature + expanded gene set
Progression markers – longitudinal - drug effects

ADtect®
DiaGenic for early Alzheimer's Disease detection

IVD
96 gene signature
Bi-nomic AD

ADtect
CSF-18F PET support

MCItect
Bi-nomic
MCI to AD

IVD
Multi-nomic AD
MCI
AD

Potential imaging partner
pre-qualification
into high end imaging?

Potential imaging partner
pre-qualification
into high end imaging?

Merz:
non-exclusive
option
for MCItect
co-development

Pre 2010

2011

August 2010

FOR EARLY DISEASE SIGNATURES

DiaGenic

DiaGenic's Partner Discussions
August 2010

- Multiple ongoing pharma interactions
  - Therapeutics
  - High-end Diagnostics

- DiaGenic invited into Phase II and Phase III development (R&D collaboration)

- Protocols exchanged for new progression and drug effect marker (expanded gene signature)

- Strong IP position: Freedom to operate
  - Freedom to operate as an independent 3 party provider of IVD in AD
  - Expansion of gene signatures and to piggy back on DiaGenic main patent classes/claims

Agenda: 2nd Quarter 2010 Presentation

- 🔴 2nd Quarter Highlights
- 🔴 Product Development & Commercial Strategies
- 🔴 2nd Quarter Finance
- 🔴 Outlook

DiaGeniC

Finance, Income

Income
(thousand NOK)

|	Q1 09	Q2 09	Q3 09	Q4 09	Q1 10	Q2 10
■ Operating revenue	5	-	-	125	-	8
■ Grants	741	1 379	688	1 504	863	971

- Research grants in 1H 2010 consisted of support from:

  - Innovation Norway

  - EU Commission (SPIDIA)

  - The Research Council of Norway (Parkinson's disease)

DiaGeNic

Finance,
Profit & Loss

Comprehensive income
(thousand NOK)

	1H 09			1H 10	
	-18,835			-22,350	

	Q1 '09	Q2 '09	Q3 '09	Q4 '09	Q1 '10	Q2 '10
Comprehensive income	-11 375	-7 460	-9 268	-11 229	-11 816	-10 534

Other Operating Cost
(thousand NOK)

	1H 09			1H 10	
	19,130			22,194	

	Q1 09	Q2 09	Q3 09	Q4 09	Q1 10	Q2 10
Salaries and related	5 710	3 625	5 252	6 687	6 374	4 202
Depreciation and Write downs	226	226	253	614	235	235
Other operating cost	5 684	3 664	3 765	3 913	5 131	6 018

Finance, Financing

Cash and Cash equivalents
(million NOK)

	Q2 '09	Q3 '09	Q4 '09	Q1 '10	Q2 '10
▪ Cash	8,1	7,7	35,4	32,9	19,8

- Share issue completed in the first half of 2010
  - Issue of 3,5 million shares with gross proceeds of NOK 9.6 million

- Warrants issued in the first half of 2010
  - 16 million warrants issued
  - Subscription price: NOK 3.25 per share
  - May be exercised up to 22 September 2010

D i a G e n i c

Finance,
Process to exercise warrants

- Process for exercising warrants
  - Reference is made to Prospectus dated 21 January 2010, section 4.12.
  - Information regarding exercising warrants will be listed on our web page: www.diagenic.com under Investor Relations
  - Key dates for exercising warrants are shown below:

Dates when share capital increases are reported to the Norwegian Register of Business Enterprises:

Due dates for requests to exercise warrants and due dates for when payment for new shares shall be made:

30 September

- 22 Sept.

Agenda: 2nd Quarter 2010 Presentation

- ♦ 2nd Quarter Highlights
- ♦ Product Development & Commercial Strategies
- ♦ 2nd Quarter Finance
- ♦ Outlook

DiaGenic

Outlook

- Accelerate the companion diagnostics strategy, including marketing of our biomarkers to the pharmaceutical and imaging industry, leading to partnering agreements.

- Gain market acceptance of BCtect® and ADtect® in selected countries in Europe.

- Continue with ADtect® US market entry plan

Conclusion

- Rx – Companion Diagnostics – Key focus area
  - Expressed interest from multinational imaging and pharmaceutical-companies for partnership with DiaGenic.
    - Active dialogue on supporting phase II and III studies
    - New tools pursued on disease progression and on early disease stage
    - Through the development of MCItect® DiaGenic has a leading biobank of samples
    - DiaGenic has unique competitive advantage and capabilities in developing biomarkers

- MDx – Molecular diagnostics
  - BCtect® - Available now in private clinics in UK and Finland
  - ADtect® - Signed agreement with Ferrer, launching first in Spain and Germany
  - Marketing barriers remains high, large players are instrumental to drive revenue and income

- At current cost levels the company is financed for a period of less than one year. Work is thus proceeding to secure financing of the Company, including but not limited to exercise of warrants and equity financing.

For more information, see www.diagenic.com

DiaGenic ASA

Grenseveien 92, N-0663 Oslo, Norway

Tel +47 23 24 89 50

Mail: diagenic@diagenic.com

www.diagenic.com

Disclaimer

This presentation includes forward-looking statements regarding DiaGenic ASA, including projections and expectations, which involve risk and uncertainty. Such statements are included without any guarantees to their future realization. Although DiaGenic believes that the expectations regarding the Company reflected in such forward-looking statements are based on reasonable assumptions, no assurance can be given that such projections will be fulfilled. Any such forward-looking statement must be considered along with knowledge that actual events or results may vary materially from such predictions due to, among other things, political, economic, financial or legal changes in the markets in which DiaGenic does business, and competitive developments or risks inherent to the Company's business plans. Many of these factors are beyond DiaGenic's ability to control or predict. Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. The Company does not intend, and does not assume any obligation, to update the forward-looking statements included in this presentation as of any date subsequent to the date hereof.

Solid IP, backed by 10 years of R&D
> 100 patents accepted or granted

4 patent families granted, accepted by examiner, or in process

Family 1	a. Method to identify diseases using blood samples and gene expression technology, where the sample is collected distant to the area of the disease b. Method to identify diseases using non-sequence based gene expression methods	a. Covers both sequence based and non-sequence based gene expression methods. Granted for Alzheimer in US, Europe, and Hong Kong. Broad patent, including Alzheimer, in Japan and Norway. b. No disease limitations, no sample limitations. Granted in Europe, Norway and Hong Kong
Family 2	Describes sets of gene sequences that can be used to develop expression signature for the detection of diseases	Granted in South Africa. Granted in Australia, New Zealand and Europe for Alzheimer and Breast Cancer, and for breast cancer in India
Family 3	Describes gene families and genes expressed in blood which can be used to detect cancer	Accepted in Europe, Granted in South Africa and New Zealand
Family 4	Describes oligonucletide probes in kit form that can be used to identify, diagnose and monitor breast cancer	Application filed 2010

20 Largest Share Holders - August 18th 17:00

Shares	Percent	Name
3 963 795	5.64	Tredje AP-Fonden C/O HANDELSBANKEN AS
2 907 370	4.14	LØNNEBORG ERIK ANDERS
2 599 670	3.70	NORDEA NORDIC EQUITY
2 490 764	3.55	SHARMA PRAVEEN
1 903 224	2.71	SIX SIS AG 25PCT
1 892 178	2.69	HOLBERG NORDEN V/HOLBERG FONDSFORVA
1 421 959	2.02	HOLBERG NORGE V/HOLBERG FONDSFORVA
1 363 600	1.94	JPMORGAN CHASE BANK NORDEA TREATY ACCOUN
1 267 667	1.80	SKAGEN VEKST
1 220 000	1.74	HAAVIND KARL WILHELM
1 003 100	1.43	LIVSFORSIKRING.NORDE JP MORGAN CHASE BANK
1 000 000	1.42	A/S SKARV
923 082	1.31	STOREBRAND VEKST JPMORGAN EUROPE LTD,
848 000	1.21	AMFIBIEN AS V/ JOHN HESTAD
820 000	1.17	NARMO SIGRID
813 300	1.16	VPF NORDEA SMB C/O JPMORGAN EUROPE
804 231	1.15	NORDNET BANK AB
755 000	1.07	GJØRLING KENNETH RAYMOND
693 278	0.99	STORHAUG DAG ERIK
655 000	0.93	KIKUT AS
29 345 218	**41.77**	**Sum**

FOR EARLY DISEASE SIGNATURES

DiaGENiC